Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages

Shares of Alpha Cognition Inc. (NASDAQ:ACOG) have received an average recommendation of “Buy” from the four analysts that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $17.25.

ACOG has been the topic of several research reports. B. Riley Financial began coverage on shares of Alpha Cognition in a research report on Thursday. They issued a “buy” rating on the stock. HC Wainwright increased their target price on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Monday. Craig Hallum restated a “buy” rating and set a $17.00 price target on shares of Alpha Cognition in a research note on Friday, August 14th. Raymond James Financial assumed coverage on shares of Alpha Cognition in a report on Friday, July 10th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday.

Alpha Cognition Price Performance

Shares of Alpha Cognition stock traded up $0.32 during trading hours on Wednesday, hitting $8.89. 140,146 shares of the company’s stock traded hands, compared to its average volume of 128,612. The stock has a market capitalization of $193.62 million, a price-to-earnings ratio of -8.08 and a beta of 2.31. Alpha Cognition has a 12-month low of $4.50 and a 12-month high of $10.00. The company has a fifty day simple moving average of $7.91 and a 200-day simple moving average of $6.59.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The company had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $4.38 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%. On average, analysts forecast that Alpha Cognition will post -1.42 EPS for the current fiscal year.

Institutional Trading of Alpha Cognition

Several hedge funds have recently made changes to their positions in ACOG. Geode Capital Management LLC purchased a new position in shares of Alpha Cognition during the 2nd quarter valued at $112,000. Marshall Wace LLP purchased a new stake in Alpha Cognition in the 2nd quarter worth about $600,000. Cable Car Capital LP increased its holdings in Alpha Cognition by 68.8% in the 2nd quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock worth $8,108,000 after acquiring an additional 354,278 shares during the last quarter. Massar Capital Management LP purchased a new stake in Alpha Cognition in the 2nd quarter worth about $116,000. Finally, Manatuck Hill Partners LLC raised its stake in Alpha Cognition by 74.6% in the 2nd quarter. Manatuck Hill Partners LLC now owns 117,000 shares of the company’s stock valued at $1,092,000 after acquiring an additional 50,000 shares during the period.

Key Alpha Cognition News

Here are the key news stories impacting Alpha Cognition this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, well above recent trading levels. The firm also raised its Q1 2027 EPS estimate to a loss of $0.12 from $0.19 and lifted its FY2027 forecast to a loss of $0.31 from $0.32.
• Positive Sentiment: The analyst expects Alpha Cognition to reach approximately breakeven in Q4 2027, revising the forecast to $0.01 EPS from a $0.01 loss. This suggests improving longer-term operating trends, although profitability remains distant.
• Neutral Sentiment: HC Wainwright’s updated forecasts remain broadly aligned with the company’s loss-making profile: losses of $1.33 per share in FY2026 and $0.31 per share in FY2027, compared with the current-year consensus estimate of a $1.34 loss.
• Negative Sentiment: The firm reduced its FY2026 EPS estimate to a loss of $1.33 from $1.08 and cut Q3 2026 EPS expectations to a loss of $0.33 from $0.20. Q4 2026 was also lowered to a $0.25 loss from $0.20.
• Negative Sentiment: Q2 2027 and Q3 2027 estimates were reduced to losses of $0.13 and $0.07 per share, respectively. These revisions indicate that near-term expenses and cash-burn concerns may be greater than previously expected.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.